CN112921090A - 细胞外囊泡circRNAs作为胃癌诊断标志物的应用 - Google Patents

细胞外囊泡circRNAs作为胃癌诊断标志物的应用 Download PDF

Info

Publication number
CN112921090A
CN112921090A CN202110206105.2A CN202110206105A CN112921090A CN 112921090 A CN112921090 A CN 112921090A CN 202110206105 A CN202110206105 A CN 202110206105A CN 112921090 A CN112921090 A CN 112921090A
Authority
CN
China
Prior art keywords
gastric cancer
chr1p11
chr10q11
circrna
extracellular vesicle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110206105.2A
Other languages
English (en)
Other versions
CN112921090B (zh
Inventor
张义
董召刚
肖珂
王洪春
王立水
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qilu Hospital of Shandong University
Original Assignee
Qilu Hospital of Shandong University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qilu Hospital of Shandong University filed Critical Qilu Hospital of Shandong University
Priority to CN202110206105.2A priority Critical patent/CN112921090B/zh
Publication of CN112921090A publication Critical patent/CN112921090A/zh
Application granted granted Critical
Publication of CN112921090B publication Critical patent/CN112921090B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

本申请提供细胞外囊泡circRNAs作为胃癌诊断标志物的应用,所述circRNAs为Chr10q11、Chr1p11、Chr7q11中的至少一种。本发明通过高通量深度测序表达验证证明,细胞外囊泡circRNA Chr10q11、Chr1p11、Chr7q11可作为诊断胃癌的生物标志物,并开发了相应的检测试剂盒,该试剂盒检测灵敏度高、特异性高、检测方便,满足诊断胃癌病人的检测需求,经临床验证诊断准确率高,具有良好的实际应用之价值。

Description

细胞外囊泡circRNAs作为胃癌诊断标志物的应用
技术领域
本申请涉及本发明属于诊断标志物技术领域,具体涉及细胞外囊泡circRNAs作为胃癌诊断标志物的应用。
背景技术
公开该背景技术部分的信息仅仅旨在增加对本申请的总体背景的理解,而不必然被视为承认或以任何形式暗示该信息构成已经成为本领域一般技术人员所公知的现有技术。
胃癌是一种常见的消化道恶性肿瘤,是全球癌症死亡的第三大原因。其发病率在全球恶性肿瘤中位居第五位,死亡率高居第三位,严重威胁着人类的健康。我国胃癌年发病率和死亡率分别为36.21/100,000和25.88/100,000,在恶性肿瘤中居第2位,仅次于肺癌。胃癌的致病因素多样,发展过程复杂,晚期胃癌患者的5年生存率仅为5%-20%,中位总生存期为10个月。由于胃癌发病症状隐匿,且易发生淋巴结及远处转移,绝大多数胃癌患者在初次就诊时就被确诊为肿瘤晚期。因此,早期发现胃癌对提高生存率至关重要。目前,胃癌的发现手段主要包括胃镜及活组织检查、影像学检查(钡餐、CT等)、肿瘤标志物等实验室检查,其中病理活检是诊断的金标准,但其高昂的价格、有创性及不适性限制了其应用。影像学检查对肿瘤的解剖结构显示较好,但对于直径较小的病灶通常不易显示。外周血生物标志物检测是GC筛选的理想方法,传统的肿瘤标志物有癌胚抗体(CEA)、糖类抗体19-9(CA19-9)和糖类抗体72-4(CA72-4)。然而,传统的肿瘤标志物在胃癌诊断的敏感性和特异性上均存在不足,限制了其临床应用价值。因此,寻找具有较高敏感性和特异性的胃癌诊断标志物是迫切需要的。
细胞外囊泡是在生理或病理条件下释放的一组细胞来源的亚微米囊泡。根据细胞外囊泡的大小和生物发生机制,其被分类为外泌体(30-100nm)、微囊泡(MVS,100-1000nm)和凋亡小体(0.1-5μm),其表面标志物为CD63、CD9、TSG101等,具有脂质双分子层结构。研究显示细胞外囊泡参与肿瘤的发生发展及功能调控,如增殖、迁移、血管生成、免疫调节等。细胞外囊泡可以被肿瘤细胞释放入肿瘤微环境,进而进入外周循环,研究已经证实,细胞外囊泡稳定存在于外周血中,且在胃癌时表达升高,是具有良好应用前景的肿瘤标志物。细胞外囊泡几乎在所有的体液中检测到,包括血清/血浆、胃液、胸水、腹水、唾液、乳汁、尿液、肺泡灌洗液等;细胞外囊泡来源于肿瘤细胞及微环境,其表达变化特征可以反映细胞的表型及疾病的变化。这些特性使得细胞外囊泡成为了标志物的最大优势,能够提供简便、可靠、稳定的检测。细胞外囊泡在肿瘤中发挥的重要作用能与其携载的内容物有关。研究已证实细胞外囊泡中富含非编码RNA(miRNA、lncRNA、circRNA)、DNA以及蛋白质等,细胞外囊泡中的这些内含物一方面可以作为效应分子发挥其生物学活性,参与并调控胃癌发生发展,另一方面这些效应分子也反映肿瘤的状态,是具有很大潜能的生物学标志物。
环状RNA(circRNA)分子在30年前首次被发现,但最初被认为是剪接错误的产物。RNA测序技术已经鉴定出数以千计的稳定、丰富和进化保守的circRNAs。circRNAs可以由外显子、内含子或两者组成,分别产生外显子、内含子或外显子。circRNAs的生物发生机制已经在许多综述中得到了详细的描述。简而言之,circRNAs可以通过直接后剪接或套索驱动的后剪接来连接下游3‘端和上游5’端来产生环状分子。DDX39A和DDX39B蛋白帮助circRNAs从细胞核输出到细胞质,它们分别形成短的和长的circRNAs。circRNAs通常是稳定的,因为它们独特的环状结构保护它们不被核酸外切酶切割。然而,circRNAs仍然被降解,尽管其降解机制尚不清楚。到目前为止,研究已经提出了几种可能的circRNAs降解方式:1)通过miRNA-671海绵被AGO2蛋白切割,2)通过RNaseP/MRP复合物与含有m6A修饰位点的circRNAs结合YTHDF2蛋白,或者3)通过UPF1和G3BP1结合切割。最近的一项研究。结果表明,病毒感染时,活化的RNase L可使circRNAs整体降解。此外,我们对circRNAs功能机制的了解在一定程度上可以解释它们的活性,但目前circRNAs机制研究的局限性阻碍了发现新的基因调控机制的可能性。尽管circRNAs的功能机制还没有完全被发现,但毫无疑问,它们在疾病,特别是癌症中起着重要的功能作用。circRNAs正迅速成为癌症的潜在生物标记物和治疗靶点。
由于细胞外囊泡膜的保护作用,circRNAs存在更加稳定,时间更长,且更能反映肿瘤局部状态。研究发现circRNAs的半衰期在48小时以上,远远超过miRNA的10小时。再加上其高保守性、不易被RNA核酸外切酶降解、表达的时空特异性等有点,使得其作为肿瘤标志物的应用具有良好的前景。有研究发现血清circ-0051443在肝癌时表达下调,主要存在于细胞外囊泡中,且通过miR-331-3p/BAK1通路参与肝癌进展,是新的潜在的诊断标志物及治疗靶点。Hsa-circRNA-0005795在乳腺癌组织及血清细胞外囊泡中表达均上调,通过竞争性RNA机制参与肿瘤进展,同时是新的预后标志物。目前,关于细胞外囊泡circRNAs在胃癌中作为标志物的研究较少,目前多集中于作为预后标志物的价值探讨。circ-RanGAP1在胃癌组织及血浆细胞外囊泡中表达上调,与分期、转移、预后密切相关,通过miR-877-3p/VEGFA调控胃癌细胞侵袭和迁移,参与胃癌进展,提示其可能是潜在预后监测标志物及新的治疗靶点。Hsa_circ_0000419稳定存在于血浆细胞外囊泡中,在胃癌时表达下调,是新的预后监测因子。因此,对circRNAs进行进一步的探索具有重要的意义,如能发现更加敏感和特异的胃癌早期诊断标志物,则可以做到早发现、早诊断、早治疗,显著增加患者的生存机会。
综上所述,目前有必要开发新的细胞外囊泡circRNAs标志物以用于胃癌临床诊断检测。
发明内容
针对背景技术中提出的问题,本发明目的在于探索细胞外囊泡circRNAs与胃癌的调控关系,进一步筛选具有诊断价值的诊断标志物,并提供与此相关的胃癌诊断产品。为了实现该技术目的,本发明通过高通量深度测序及临床样本表达验证证明,血清样本中的circRNA Chr10q11、Chr1p11、Chr7q11中的至少一种或多种的组合在胃癌样本与健康样本中的表达含量差异显著,可作为胃癌诊断的标记物,具有良好的临床检测价值。
具体地,本发明提供了下述的技术特征,以下技术特征的一个或多个的结合构成本发明的技术方案。
在本发明的第一方面,本发明提供了一种胃癌诊断标志物,其为细胞外囊泡circRNA Chr10q11、Chr1p11、Chr7q11中的一种或多种的组合。
其中,circRNAChr10q11的序列信息如SEQ ID NO.1中所示;circRNA Chr1p11的序列信息如SEQ ID NO.2中所示;circRNAChr7q11的序列信息如SEQ ID NO.3中所示。
在本发明的实施方式中,发明人发现细胞外囊泡circRNAChr10q11、Chr1p11、Chr7q1在胃癌中的表达均高于健康对照,对胃癌具有较好的诊断价值,三者中的至少一种、优选三种的组合可作为胃癌诊断标志物。
在本发明的第二方面,本发明提供了细胞外囊泡circRNA Chr10q11、Chr1p11、Chr7q11中的一种或多种的组合在作为胃癌诊断标志物方面的应用。
在本发明的实施方式中,所述应用包括:检测样本中细胞外囊泡circRNAChr10q11、Chr1p11、Chr7q11中的一种或多种的表达。
在本发明的实施方式中,所述样本为病理样本,包括但不限于血液、病理组织和排泄物;优选为血液,比如血清或血浆。
在本发明的实施方式中,所述检测方法包括但不限于PCR方法、免疫印迹方法、酶联免疫吸附方法和基因工程方法。
在本发明的一些实施方式中,所述细胞外囊泡circRNA Chr10q11、Chr1p11、Chr7q11作为胃癌诊断标志物应用方式如下:获取待检测对象的血液样本,提取所述血液样本细胞外囊泡中的RNA,通过PCR方法检测所述血清样本中细胞外囊泡circRNAChr10q11、Chr1p11、Chr7q11,通过扩增所述条带的长度判断待检测对象是否患有胃癌。
在本发明的第三方面,本发明提供了提取或检测细胞外囊泡circRNA Chr10q11、Chr1p11、Chr7q11中至少一种的试剂或试剂盒在制备胃癌诊断产品中的应用。
在本发明的实施方式中,所述胃癌诊断产品包括但不限于胃癌诊断试剂盒、胃癌诊断药品和胃癌诊断器械。
在本发明的第四方面,本发明提供了细胞外囊泡circRNA Chr10q11、Chr1p11、Chr7q11中的一种或多种的组合作为靶点在制备治疗胃癌的药物中的应用。
在本发明的实施方式中,所述药物抑制细胞外囊泡circRNA Chr10q11、Chr1p11、Chr7q11中的一种或多种的组合的表达。
在本发明的第五方面,本发明提供了一种胃癌诊断试剂盒,其包括细胞外囊泡circRNA Chr10q11、Chr1p11、Chr7q11中的一种或多种的组合的检测相关试剂。
在本发明的实施方式中,所述试剂盒检测样本细胞外囊泡circRNA Chr10q11、Chr1p11、Chr7q11中至少一种的表达。
在本发明的实施方式中,所述试剂盒还包括用于提取细胞外囊泡的试剂、和/或用于配制反转录反应体系的试剂、和/或用于配制qPCR反应体系的试剂。
在本发明的一些实施方式中,用于提取细胞外囊泡的试剂至少包括buffer XBP、buffer XWP、buffer XE。
在本发明的一些实施方式中,用于配制反转录反应体系的试剂至少包括反转录缓冲液(MLV-5×buffer)、dNTP混合液、RNA酶蛋白质抑制剂(RNAsin)、反转录酶液(M-MLV)和多聚胸腺嘧啶(OligodT)。
在本发明的一些实施方式中,用于配制qPCR反应体系的试剂至少包括针对circRNA Chr10q11、Chr1p11、Chr7q11的正向引物液和反向引物液;优选地还包括SYBRGreen混合液、无核酸酶纯水。
在本发明的一些实施方式中,circRNA Chr10q11、Chr1p11、Chr7q11的引物序列如如SEQ ID NO.4、SEQ ID NO.5、SEQ ID NO.6、SEQ ID NO.7、SEQ ID NO.8、SEQ ID NO.9中所示。
在本发明的第六方面,本发明提供了一种诊断和/或辅助诊断胃癌的方法,其包括检测受试者细胞外囊泡中的circRNAs;所述circRNAs为Chr10q11、Chr1p11、Chr7q11中的一种或多种的组合。
在本发明的一些实施方式中,所述细胞外囊泡的来源为血液、病理组织和排泄物;优选为血液,比如血清或血浆。
所述受试者为哺乳动物,优选为人。
通过上述技术手段,可实现以下有益效果:
(1)本发明经过高通量深度测序及临床样本表达验证,筛选得到circRNAChr10q11、Chr1p11、Chr7q11能够作为胃癌血清细胞外囊泡circRNAs的诊断标志物。
(2)本发明为将来研制提高细胞外囊泡circRNA Chr10q11、Chr1p11、Chr7q11应用提供了依据。
(3)本发明以细胞外囊泡作为胃癌血清circRNAs检测,开发了相应的检测试剂盒,该试剂盒检测灵敏度高、特异性高、检测方便,满足诊断胃癌病人的检测需求,经临床验证诊断准确率高。
附图说明
构成本申请的一部分的说明书附图用来提供对本申请的进一步理解,本申请的示意性实施例及其说明用于解释本申请,并不构成对本申请的不当限定。以下,结合附图来详细说明本申请的实施方案,其中:
图1为实施例中测序结果显示候选circRNA Chr10q11、Chr1p11、Chr7q11分子在健康对照组(Control)和胃癌组(Gastric cancer)血清细胞外囊泡中的表达水平热图。
图2为实施例中血清细胞外囊泡circRNA Chr10q11、Chr1p11、Chr7q11在健康对照组(Control)、胃癌组(Gastric cancer)表达图。
图3为本发明实施例中血清细胞外囊泡中circRNA RNAChr10q11、Chr1p11、Chr7q11及其联合分析对胃癌诊断ROC分析图。
具体实施方式
下面结合具体实施例,进一步阐述本申请。应理解,这些实施例仅用于说明本申请而不用于限制本申请的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件或按照制造厂商所建议的条件。
除非另行定义,文中所使用的所有专业与科学用语与本领域熟练人员所熟悉的意义相同。本申请所使用的试剂或原料均可通过常规途径购买获得,如无特殊说明,本申请所使用的试剂或原料均按照本领域常规方式使用或者按照产品说明书使用。文中未注明具体条件的实验方法,通常按照常规条件如J.萨姆布鲁克等编著的科学出版社年出版的《分子克隆实验指南》一书中所述的条件,或按照制造商所建议的条件。除非另行定义,文中所使用的所有专业与科学用语与本领域熟练人员所熟悉的意义相同。此外,任何与所记载内容相似或均等的方法及材料皆可应用于本发明方法中。文中所述的较佳实施方法与材料仅作示范之用。
实施例1
一、实验对象纳入与排除标准:
(一)病例来源
全部病例均来源于2016年12月至2017年12月山东大学齐鲁医院住院病人。正常对照组血样均来自于山东大学齐鲁医院健康查体者,为无心、脑、肺、肝、肾疾病和癌症疾病,无已知影响研究指标疾病。
(二)诊断标准
胃癌诊断根据组织病理学检查,分期根据UICC/AJCC TNM staging system(2010)。
(三)病例排除标准
(1)胃间质瘤;(2)12个月内使用抗生素或质子泵抑制剂(PPI)治疗;(3)免疫系统疾病史;(4)恶性肿瘤史;(5)临床资料不完整;(6)感染性疾病;(7)不愿参与本研究。
(四)健康对照纳入标准
纳入标准:(1)体格检查正常;(2)血、尿、便、血沉、肝功能、肾功能、电解质、血糖、血脂指标正常(3)心电图、腹部超声、胸部X片未见异常。
排除标准:12个月内患有糖尿病、肠易激综合征、腹腔疾病或使用抗生素和/或益生菌治疗的患者。
二、高通量检测
1、RNA质控
使用NanoDrop ND-1000仪(Thermo Fisher Scientific,Waltham,MA,USA)测量每个样品的RNA浓度。以OD260/OD280值作为RNA纯度指标。若OD260/OD280值范围在1.8~2.1,则RNA纯度合格,QC Results被标记为“Pass”,即合格。当出现以下情况时,QC Results被标记为“Fail”,即质量差:
a:OD260/OD280<1.8或>2.1;
b:样品降解;
c:RNA量<1μL,不能在凝胶上显示;
当OD260/OD280<1.8,但是满足其他指标时,QC Results被标记为“Need Pure”。
2、RNA文库制备及测序
根据供应商说明,使用Ribo-Zero rRNARemoval Kits(Illumina,美国)移除总RNA中的rRNAs。使用TruSeq Stranded Total RNA Library Prep Kit(Illumina,美国)预处理RNA,构建测序文库。使用BioAnalyzer 2100仪器(Agilent Technologies,美国)进行文库质控和定量。根据Illumina测序说明,将10pM文库变性为单链DNA分子,在Illuminaflowcell上捕获,原位扩增为簇(cluster),并在Illumina HiSeq测序仪上采用双端模式(PE mode)进行150cycle测序。
Illumina平台是一种基于边合成边测序技术(Sequencing-By-Synthesis,SBS)的测序方法。由于可逆阻断技术可以实现每次只合成一个碱基,并标记荧光基团,再利用相应的激光激发荧光基团,捕获激发光,从而读取碱基信息。高通量测序得到的原始图像数据文件经碱基识别(Base Calling)分析转化为原始测序序列,称之为Raw Data或Raw Reads,结果以FASTQ(简称为fq)文件格式存储。利用hisat2将Clean Reads与指定的参考基因组进行序列比对,获取在参考基因组或基因上的位置信息,以及测序样品特有的序列特征信息。一个基因表达水平的直接体现就是其转录本的丰度情况,转录本丰度程度越高,则基因表达水平越高。在转录组测序分析中,可以通过定位到转录本外显子区的测序序列(reads)的计数来估计基因的表达水平。转录本表达量的计算使用TMM(trimmed mean of M-values),根据测序深度和变异程度对原始junction reads进行标准化,并进行log2转化,得到logCPM值。logCPM(log2-counts-per-million),CPM即Counts per million,计算公式为CPM=C/N*1000000,设C为比对到某个基因的reads数(read count),N为比对到所有基因的总reads数。
3、数据分析
经过Illumina HiSeq 4000测序仪测序,收获双端reads。利用Q30进行质控,使用cutadapt(v1.9.3)软件去接头,去低质量reads,获得高质量reads。
circRNA:使用STAR软件将高质量reads比对到参考基因组/转录组上(UCSC hg19)上,并以Ensembl转录组(v75)gtf文件为指导,使用DCC软件进行环状RNA检测和鉴定。并使用circBase数据库和Circ2Traits对所鉴定的环状RNA进行注释。再使用edgeR软件进行数据标准化和差异表达circRNA筛选。计算倍数变化(fold change)和P-value。以倍数变化>=2.0,P-value<=0.05作为差异环状RNA的阈值,并进行差异环状RNAs的GO和KEGG分析。
4、结果
根据测序结果,设定标准(在样本中表达均稳定表达,两组间差异倍数>2,P<0.05),筛选出3个circRNAs分子(Chr10q11、Chr1p11、Chr7q11)见图1,Chr10q11、Chr1p11、Chr7q11的序列信息如SEQ ID NO.1、SEQ ID NO.2和SEQ ID NO.3中所示。
Chr10q11(SEQ ID No.1),(chr10:42385521-42396165-)大小10750bp:
TCCATTTGATCATGATTCCATTTGATTCCACTCGATGATTCCATTCGATTCCATTCAATGATGATTCCATTCGAGTTCATTGACTATTCCATTCCATTCCATTCGATGATTCCATTTGAGTCCATTCGATGATTCTATTCGATTGCATTCGATAATTCCATTCGATTGCATTTGATAATTCCATTTGATTCCATTTGAGGATAATTCCATTTGAGTCCATTCGATGATTGTTCCATTCGATTCTATTCGGTGATTCCATTCGATTCTATTTGATAATGATTCCATTCGAGACCATGCGATGATTCCATTCAATTCCATTCAATAATGATTCCATTCGAGTCCATTCAATGATTCCATTCAAGTCCATTTGTTGATTCCATCTGATTCCATTCAATGAATCCATTCGATTCCATTCTATGATGGTTCCATTCATTTCTATCTGATGATAATTCCATTCAATTCCATTCAATGATTCCATTCGATTCCATTTGATGATGATTTCAATCAATTTCATTTGATGATTCCATTCGAATCCATTTGATGATGAGTCCATCCATTTCAATTTCATAATTCCATTCGTTTCAATTCGATGGTGTTTCCATTCGATTCCATTCGATGTTAATTCCATTAGTTTCCATTGGATGATGATTCCATTTGAGTCCATTCGATCATGATCACATTGGATTTCATTCCATAATTCTATTCTATTCCATTTCATGATGATTCCATCTGATTCCATTTGATGATTCCATTCGATTCCATTCTATGATGATTCCATTCATTTCCATCTGATGATGATTCCAATTGATTCATTTCAATGATTCCATTCGATTCCATTTGATGATGATTGCAATGAATTTCATTCGATGACACCATTTGAATCCATTCGATGATGAGTCCATCCATTTCAATTTCATGATAATTCCATTCTTTTCAATTCGATGGTGTTTCCATTTGATTGCATTCGATGTTGATTCCTTTAGTTTCCATTGGATCATGATTCCATTCGAGTCCATTCGATGATCATCACATTGGATTTCATTCCATAATTCTAACCGATTCCATTTGATGATGATTCCATCTGATTCCATTTGATGATTCCATTCGATTCCATTCAATGACGATTCCATTCGTTTCCATCCAATGATGATTCCATTCGATTCCTTTCAATGATTATTCCCTTCGAGTCCATTCGATGATTCCATTCGATTCCATTCGAAGATGATTGCATTCGAGTCCATGGATTATTCCATTCCATTCCATTAGATGATTCCATTCGAGTCCATTCGATGATTATCTTCGATTCCATTCAATAATTCAGTTTGATTCCGTTTGATGTTGATTCCATTTTAGTCCATTCGATGATAATTCCATTCGATTCTATGCGATGATTCCATTCCATTCCATTTGAAGATGATTAAATTCGAGACCATTCAGTGATTGCATTCAATTCATTCGATGACGATTCCATTCAATTCCGTTCAAAGATTCCATTAGGTTTCATTTGATGATGATTCCATACGATTCCATTAGATGATGACTCCTTTCATTTCCACTCGATGATGATTCCATTCGTTTCCATTCGACGATGATTCCATTTGATTCCGTTCAATGATTATTCCATTCGAGTCCATTCGATGATTCCATTCGATTCTATTCGATGATGATTGCATTCGGGTCCATGGATTATTCCATTCCATTCCATTAGATGATTCCATTCGTGGCCATTTGATGATTCTCTTCGATTCCATTCGATAATTCCGTTTGACTCCGTTTGATGTTGATTCCATTCGAGTCCATTCAATGATAATTCCATTCGATTCTATGCGATGATTTCATTCCTTTCCATTTGATGATGATTCCATTCGAGACCATTCGATGATTGCATTCAATTCATTCGATGACGATTCCATTCAATTCCATTCAATGATTCCATTAGATTCCATTTGATGATGATTCCATTCGATTCCATTCAATGATGATTCCATTCGAGTTCATTGACTATTCCATTCCATTCCATTCTATGATTCCATTCGAGTCCATTAGATGATTCTATTCGATTGCATTTGATAATTCCATTCGATTGCATTCGATATTTCCATTCGATTCCATTTGAGGATAATTCCATTTGAGTCCATTCAATGATTCTTCCATTCGATTCTATTCGGTGATTCCATTCGATTCCATTTGATGATGATTCCATTAGAGACCATTCCATGATTCCATTCAATTCCATTCAATAAAGATTGCATTCGAGTCCATTCAATGTTTCCATTCAAGTCCATTCAATGATTCCATCTGATTCCATTCAATGAATCCATTCGATTCCATTCTATGATGATTCCATTCATTTCCATCTGATGATGATTCCATTCGATTCCATTCAATGATTCCATTCGATTCCATTTGATGATGATTTCAATCAATTTCATTCGATGATTCCATTCGAATCCTTTCGATGATGAGTCCATCCATTTCAAATTCATGATAATTCCATTCCTTTCAATTCGATGGTGTTTCCATTCGATTCCATTCGATGTTGATTCCATTAGTTTCCATTGGATGATGATTCCGTTCGAGTCCATTCGATGATGATGACATTGGATTTCATTCCATAATTCTACTCGATTCCATTTGATGATGATTCCGTCTGCTTCCATTTGATGATTCCATTCGATGCCATTCGATGATGATTCCATTCGATTCCGTTCAATGATTATTCCACTCGTGTCCATTCGATGATTCCATTCGATTCCATTCGATGATGATTGCATTCGAGTCCATGGAATACTCCATTCCATTCCATTAGATGATTCCATTCGAGTCCATTCGATGATGCTCTTCGATTCCATTCGATAATTCCGTTTGATTCCGTTTGATGTTGATTCAATTCCAGTCCATTCGATGATAATTCCATTCGATTCTATGCGATGATTCCATTCTAATCCATTTGAAGATGATTCCATTCGAGACCATTCGATGATTGCATTCAATACATTCTATGACGATTCCATTCAATTCCGTTCAATGATTCCATTCGATTCCATTTGATGATGATTCCATTCGATTCCATTTGATGAAGATACCATGCGATTCCATTAGATGATGACTCCTTTCATTTCCATTCAATGAGGATTCCATTCGGTTCCATTTGATGATGATTCCTTTGAATTCCATTGGATGACAATTCCATTCAATACCAATTGATTATGGTTATTTTTGATTCCGTTTGATGATGATTATATTCGATTCCATTTGATCATGGTTCCATTCGATTCCACTCAATGATTCCATTCGATTCCATTCAATGATTATTCCATTCGAGTTCATTGACTATTCCATTCCATTCCATTCGACGATTCCAATCGAGTCCTTTCGATGATTCTATTTGATTGCATTCGATAATTCCATTCGATTGCATTCGATAATTCCATTCGATTCCATTTGAGGATAATTCCATTTGAGTCCATTCGATGATTGTTCCATTCGATTCTATTCGGTGATTCCATTCGATTCCATTTGATAAGGATTCCTTTCGAGACCATTCGATGATTCCATTCAATTCCATTCAATAATGATTTCATTCGAGTCCATTCAGTGATTGCATTCAAGTCCTCTTGATGATTCCATCTGATTCCATTCAATGAATCCATTCGATTCCATTCTATGATGATTCCATTCGTTTCCATCTGATGATGATTCCATTCGATTCCATTCAATGATTCCATTCGATTCAATTTGATGATGATTTCAATCAATTTCATTCGATGATTACATTTCGAATCCATTCGATGATGAGTCCATCCATTTCAATTTCATGATAATTCCATTCGTTTCAATTCGATGGTGTTTCCATTCGATTCCATTCGATGTTGATTCCATTAGTTTCCATTGGATGATGATTCCATTCGAGTCCATTCGATGATGATCACATTGGATTTCATTCCATAATTCTACTCAATTCCATTTGATGATGATTCCATCTGATTCCATTTGATGATTCCATTCAATTCCATTCGATGATGATTGCATTCGTTTCCATCCAATGATGATTCCATTCGATTCCGTTGAATGATTGTTCCATTCGAGTCCATTCGATGATTCCATTCGATTCCATTCGATGATGAGAGCATTCGAGTCCATGGATTATTCCATTCCATCCCATTAGATTATTTCATTCGAGTCCATTCGATGATTCTCTTCGATTGCATTTGATAATCCCGTTTGATTCCGTTTGATGTTGATTCCATTTGAGTCCATTTGATGATAATTCCATTCGATTCTATGCGATGATTCCATTCCATTCCATTTGAAGATGATTCCATTCGAGACCATTCAATGATTGCATTAAATTCATTCGATGACGATTCCATTCAATTCCGTTCAATGATTCCATTAGAATCCATTCGATGATGATTCCATTCGATTCCATTTCATGATGATTCCATGCGATTCCATTAGATGATGACTCCTTTCACTTCCATTCGATGATGATTCCATTCGTTTCCATTCGACGATGATTCCATTTGATTCCGTTCAATGATTATTCCATTCGAGTCCATTCGATGATTCCATTCGATTCTATTCGATGATGATTGCATTCGGGACCATGGATTATTCCATTCCATTCCATTAGATGATTCCATTCGTGGCCATTCGATGATTCTCTTCGATTCCATTCGATAATTCCGTTTGATTCCGTTTGATGTTGATTCCATTCGACTCCATTCAATGATAATTCCATTCGATTCTTTGCGATGATTCCATTCCTTTCCATTTGATGATGATTCCATTCGAGACCAATCGATGATTACATTCAATTCATTCGATGACGATTCCATTCAATTCCTTTCAATGATTCCATTAGATTCCATTTGATGATGATTCCATTCAAATCCATTTGATGATGATTCCATGCGATTCCATTATTTGATGACTCCTTTCATTTCCATTCAATGAGGTTTCCATTCGGTTCCATTTGATGATGATTCCTTTGAATTCCATTTGATGACAATTCCATTCAATACCAATTGATGATTGTTATTTTTGATTCCATTTGATGATTACATTCGATTCCATTTAATCGTGATTCCATTCGATTCCACTCGATGATTCCATTCGATTCCATTCAATGATGATTCCATTCGAGTTCATTGACTATTCCATTCCGTTCCATTCGATGATACCATTCGAGTCCATTCGATGATTCTACTCGATTGCATTCGATAATTCCATTCGATTGCATTTGATAATTCCATTTGATTCCAGTTGAGGATAATTCCTTTTGAGTCCATTCGATGATTGTTCCATTCGATTCTATTCGGTGATTCCATTCGATTCCATTGGATAATGATTCCATTCAATACCATTCGATGATTCCATTCTATTCCATTCAATAATGATTCCATTCGAGTCCATTCAATGATTCCATTCAAGTCCATTCGATGATTCCATCTGATTCCATTCAATGAATCCATTCGATTCCATTATATGATGATTCCATTCATTTCCATCTGATGAGGATTCCTTTCGATTCCATTCAATGATTCCATTCGATTCAATTTGATGATGATTTCAATCAATTTCATTCGATGATTCCATTCGAATCCATTCGGTGATGAATCCATCCATTTCAATTTCATGATAATTCCATTCATTTCAATTCGATGGTGTTTCCATTCGATTCCATTCGATGTTGATTCCATTAGTTTCCATTGGATGATGGTTCCATTCGAGTCCATTCAATGATGATCACATTGGATTTCATTCCATAATTCTATTCGATTCCATTTGATGATGATTCCATCTGATTCCATTTGATGATTCCATTCGATTCCATTCGATGATGATTCCATTCGTTTCCATCTGATGATGATTCCATTCGATTCCGTTCAATATTTATTCCATTCGAGTCCATTTGACGATTCCATTTAATTCCATTTGATGATGATTGCATACGAGTCCATCAATTATTCCATTCTATTTCATTAGATGATTCCATTCGAGTCCATTCGATGATTCTCTTCGATTCCATTCGATAACTCCGTTTGATTCCGTTTGATGTTGATTCCATCTGAGTCCTTTCGATGATAATTCCATTCGAATCTATACGATGATTCCTTTCCATTCCATTTGGAGATTATTCCATTCGAGACCATTCGATGATTGCATTCAATCCATTCGATGACGATTCCTTTCAATTCCCTTCAATGATTCCATTAGATTCCATTCGATGATGATTCCATTCGATTCCATTTGATGATGATTCCATGCGATTCCAATAGATGATGACTCCTTTCATTTCCATTCGATGATGTTTCCATTCGTTTCCGTTCGGCGATGATTCCATTCGATCCCGTTCAATGATTATTCCATTCGAGTTCATTTGATGATTCCATTGGGTTCTATTCGATGATGATTGCATTCGTGTCCATGGATAATTCCATTCCATTCCATTAGATGATTCCATTCGTGGCCATTCGATGATGCTCTTCGATTCCATTCGATAATTCCGTTTGATTCCGTTTGATGTTTATTCGATTTGAATCCATTCAATGATAATTCCATTCGATTCTATGCGATGATTCCATTCCTTTCCATTTGAAGATGATTCCATTCCAGACCATTCGATGATTGCATTCAATTCATTCGATGACGATTCCATTCAATTCCGTTCAATGATTCCATTCGATTCCATTTGATGATGATTCCATGCGATTCCATTAGATGATGACTCCTTTCATTTCCATTCAATGAGGATTCCATTCGGTTCCATTTGATGATGATTCCTTTGAATTCCATTTGATGACAATTCCATTCAATACCAATTGACGATGTTTATTTTTGATTCCATTTGATGATGATTACATTCGATTCCATTTGATGATGATTCCATTTGATTCCACTCGATGATTCCATTCTATTCCATTCAATGATGATTCCATTCGAGTTCATTGACTATTCCATTCCATTCCATTCGATGATTCCATTCGAGTCCATTCGATGATTCTATTTGATTGCATTCGATAATTCCATTCGGTCCATTCGATAATTCCATTTGATTCCATTTGAGAATAATTCCATTTGAGTCCATTTGATGATTGTTCCATTCGATTCTATTCGGTGATTCCATTCGATTCCAATTGATAATGATTCCATTCGAGACCATTCGATGATTACTTTCTATTCCATTCAATAATGATTCCATTCGAGTCCATTCAATGATTCCATTCAAGTCCATTCGATGATTCCTTCTGATTCCATTCAATGAATCCATTCGAATCCATTGTTTGATGATTCCATTCATTTCCATCTGAAGATGATTCCATTCGATTCCATTCAATGATTCCATTCGATTCCATTCGATGATGATTCCATTCGTTTCCATCTGATGAAGATTCCATTCGATTCCGTTCAATGTTTACTCCATTTGATTCCATTCGCTGATTCCATTCGATTCCATTTGATGATGATTGCATTCGAGTCCATGGATTATTCCATTCTATTTTATTAGATGATTCCATTCGTGGCCATTTGATGATTCTCTTCGATTCCATTCGATAATTCCGTTTGATTCCGTTTGATGTTCATTCCATTCGTTTCCTTTCAATGATTCCATTCAAGTCCATTCGATGATTCCATCTGATTCCATTCAATGAATCCATTCGATTCCATTCTATGATGATTCCATTCTTTTCCATCTGATGATGATTCCATTCGATTCCATTCAATGATTCCATTCGATTCCATTTGATGATGATTTCAATCAATTTCATTCGATGATTCCATTCGAATCCATTCGATGATGAGTCCATCCATTTCAATTTCATGATAATTCCATTCGTTTCAATTCGATGGTGTTTCCATTCGATTCCATTCGATGTTGATTCCATTAGTTTCCAGTGGATGATGATTCCGTTCGATTCCATTTGATGATGATCACATTGGATTTCATTCCATAATTGTATTTGATTCCATTTGATGATGATTCCATCTGATTCCATTTCATGATTCCATTCGATTCCATTCGATAATGATTCCATTCGTTTCCATCCGATGATGATTCCATTCGATTCCGTTCAATATTTATTCCATTCGAGTCCATTCGACGATTCCATTCGATTCCATTTGAGGATGATTGCATTCTAGTCCATGGATTATTCCATTCTATTTCATTAGATGATTCCATTCGAGTCCATTCGATGATTCTCTTCGATTCCATTCGATAATTCCGTTTGATTCCGTTTGATGTTGATTCCATTTGAGTCCATTCGATGTTAATTCCATTCGATTCTATGCGATGATTCCATTCCATTCATTTTGAAGATGATTCCATTCGAGACCATTCGATGATTGCATTCAATTCATTCGATGATGATTCCATTCAATTCCGTTCAATGATTCCATTAGATTCCATTCGATGATGATTCCATTCGATTCCATTTGATGATGATTCCATGCGATTCCATTGGATGATGACCCCTTTCATTTCCATTCTATGATGATTCCATTTGTTTCCTCCATTCGACGATGATTCCATTCGATTCCGTTCAATGATTATTCCATTCGAGTCCATACGATGATTCCATTCGATTCTATTCGATGATGATTACATTCGTGTCCATGGATTATTTCATTCCATTCCATTAGAGGATTCCATTCGAGGCCATTCGATGATTCTCTTCGATTCCATTCGATAATTCCGTTTGATTCCGTTTGATGTTGATTCCATTCGAGTCCATTCAATGACAATTCCATTCGATTCTATGCGATGATTCCATTCCTTTCCATTTGAAGATGATGCCATTCGAGACCATTCGATGATTGCATTCAATTCATTCGATGACGATTCCATTCAATTCTGTTCAATGATTCCATTAGATTCCATTCGATGATTATTCCATTCGATTCCATTTGATGATGATTCCATGCGATTCCATTAGATGATGATTCCTTTCATTTCCATTCAATGAGGATTCCATTCGGTTCCATTTGATGATGATTCCTTTGAATTCCATTTGATGACAATTCCATTCAATACCAACTGATGATGGTTATTTTTGATTCCATTTGATGATGATTACACTTGATTCCATTTGATCATGATTCTATTCGATTCCACTCGATGATTCCATTCGATTCCATTCAATGATGATTCCATTCGAGTTCATTGACTATTCCATTCCATTCCATTCGATGATTCCATTCGAGTCCATTCGATGATTCTATTTGATGGCATTCTATAATTCCATTCGATTGCATTTGATAAATCCATTCAATTCCATTTGAGGATAATGCCATTTGAGTCCATTCCATGATTGTTCCATTCGATTCCATTCGATAATTATTCCATTCGATTCCATTTGATAATGATTCTATTCGAGACCATTCGATGATTCCATTGAATTCCATTCAATAATGATTCCATTCGAGTCCATTCAATGTTTCCATTCAAGTCCATTCGATGATTCTATGTGATTCCATTCAATGAATCCATTCGATTCCATTCAATGATGATTGCATTCATTTCCATATGATGATGATTCCATTCGATTCCATTCAATGATTCCATTCGATTCCATTAGATGATGATTTCAATCAATTTCATTCGATGATTCCATTCGAATCCATTCGATGATGAGTCCTTCCTTTTCAATTTCATGATAATTCCATTCGTTTCAATTCGATGGTGTTTCCATTCGATTCCATTCGATGTTGATTCCATTAGTTTCCATTGGATGATGATTCCATTCAAGTCCGTTCGATGATGATCACATTGGGTTTCATTCCATAATTCTATTCGATTCCATTTGATGATGATTCCATCTGATTCCATTTGATGATTCCATTCCATTCAATTCGATGATGATTCCATTCGTTTCCATCCGGTGAAGACTGCATTGGATTCCGTTCAATGTTTATTCCTTTCGAGTCCATTCGACGATTCCATTCGATTCCATTCGATGATGATTCCATGCGATTCCATTTGATGATGATTCCATGCGATTCCATTAGATGATGACTCCTTTCATTTGCATTCGATGATGATTCCATTTGTTTCCGTTCGACGATGATTCCATTCGATTCCGTTCAATGATTATTCCATTCGAGTCCATTCGATGATTCCATTCGATTCTATTCGATGATGATTGCATTCGAGTCCATGGATTATTCCATTCCATTCCATTAGATGATTCCATTCGTGGCCATTCGATGATTCTTTCCGATTCCATTCGATAATTCCGTTTGATTAAGTTTGATGTTGATTCCATTCGGTCCATTCAATCATAATTCCATTCGATTCTATGCGATGATTCCATTCCTTTCCATTTGTAGATGATTCCATTCGGGACCATTCGATGATTGCATTCAATTCATTAGATGACGGTTCCATTCAATTCCGTTCAATGATACCATTAGATTTGATTTGATGATGATTCCATTTAATGATGATTCCATTCGATTCCATTTGATGATGATTCCATGCGATTCCATTAGATGATGACTCCTTTCATTTCCATTCAATGAGGATTCCATTCGGTTCCATTTGATGATGATTCCTTTGAATTCCATTTGATGACAATTCCATTCAATACCAATTGATGATGGTTATTTTTGATTCCATTTGATGATGATTACATTCGATTCCATTTGATCATGATTCCATTTGATTCCACTCGATGATTCCATTCGATTCCATTCAATGATGATTCCATTCGAGTTCATTGACTATTCCATTCCATTCCATTCG
Chr1p11(SEQ ID No.2)(chr1:121485002-121485340+)大小408bp:
CTCTGTTTGTAAAGTCTGTAAGTGGATATTCTGACATCTTGTGGCCTTCGTTGGAAACGGGATTTCTTCCTATTCTGCTAGACAGATGAATTCTCAGTAACTTCCTTGTGTTGTGTGTATTCAACTCACAGAGTTGAACGATCCTTTACACAGAGCAGACTTGAAACACTCTTTTTGTGGAATTTGCAAGTGGAGATTTCAGCCGCTTTGAGGTCAATGGTAGAAAAGGAAATATCTTCGTATAGAAACAAGACAGAATGATTCTCAGAAACTCCTTTGTGATGTGTGCGTTCAACTCACAGAGTTTAACCTTTCTTTTCATAGAGCAGTTAGGAAACACTCTGTTTGTAAAGTCTGTAAGTGGATATTCTGACATCTTGTGGCCTTCGTTGGAAACGGGATTTCTTC
Chr7q11(SEQ ID No.3),(chr7:61967596-61970486+)大小3029bp:
GCAAGTGGAGATTTCTAGCCATTTGATGCCAACAGTGGAAAGGGAAATATCTTCAAATAAAAACTAGACAGAATCATCCTCAGAAAATTCTTTGTGATGTGTGCGTTCAACTCACATAGTTTAACCTTTCTTTTTATAGAGCAGTTTGGAAACACTTTGTTGGTAACGTCTGCAAGTGGATATATGGAACGCTTTGAGGCTTTCGTTGGAAACGGGATTTCTTCATTTCATGCTAGACAGAAGAATTCTCAGTAACTTCTTTGTGTTGTGTGTATTCAACTCACAGACTGGAACGTCGCTTTACACAGAGCAGATTTGAAACACTCTTTTTGTGGAATTTGCAAGTGGAGATTTCAAGCGATTTGATGCCAACAGTAGAAAAGGAAATATCTGCAAATAAAAACAAGACAGAATCATTCTCAGAAAGTGCTTTGTGATGTGTGCGTTCAACTCACAGAGTTTAACCTTTCTTTTCATAGAGGAGTTTGGAAACACACTGTTTGTAAAGTCTGCAAGTGGATATATGGACCTGTTTGAGACCTTCGGTGGAAACGGGATTTTAACATATAATGCTAGACGGAAGAATTCTCAGTAAATTCTATGTGTTGTGTGCTTTCAACTCACATAGTTTAACCTTTCTTTTCATAGAGCAGTTTGGAAACACTCTGTTGGTAATGTCTGCAAGTGGATATATGGACCGCTTGGAGGCTTTCGTTGGAAACGGGATTTCTTCATTTCATGCTAGACAGAAGAATTCTCAGTAACTTCTTTGTGTTGTGTGTATTCAACTCACAGACTGGAACGTCCCTTTACACAGAGCAGATTTGAAACACTCTTTTTGTGGAACTTGCAAGTGGAGATTTCAAGCGATTTGATGCCAACAGTAGAAAAGGAAATATCTGTAAATAAAAACAAGACAGAATCATTCTCAGAAAGTGCTTTGTGATGTGTGCGTTCAACTCACAGAGTTTATCCTTTCTTTTCATAGAGGAGTTTGGAAACACACTGTTTGTAAAGTCTGCAATTGGATATATGGACCTGTTTGAGGCCTTCGTTGGAAACGGGATTTTATCATATAATGCTAGACGGAAGAATTCTCAGTAAATTCTTTGTGTTGTGTGCATTCAACTCACAGAGTGGAACGTCCCTTTAGACAGAGCAGATTTGAAACACTGTTTTTGCGGAATTTGCAAGTGGAGATTTCTAGCCATTTGATGCCAACAGTAGAAAGGGAAATATCTTCAAATAAAAACCAGACAGAATCATTCTCAGAAAATTCTTTGTGATGTGTGCGTTCAACTCACATAGTTTAACCTTTCTTTTCATAGAGCAGTTTGGAAACACTCTGTTTGTAAAGTCTGCAAGTGGATATATGGACCGCATTGAGGCCTTCGTTGGAAACGGGATTTCTTCATTTCATGCTAGACAGAAGAATTCTCAGTAACTTCTTTGTGCTGTGTGTATTCAACTCACAGAGTGGAACGTCCCTTTACACAGAGCAGATTTGAAACACTCTTTTTGTGGAATTTGCAAGTGGAGATTTCAAGCGATTTGATGCCAACAGTAGAAAAGGAAATATCTTCAAATAAAAACTAGACAGAATCATTCTCAGAAACTACTTTGTGATGTGTGCCTTCAACTCACAGAGTTTAACCTTTCTTTTCTTAGAGCAGTTTAGAAACACTCTGCTTGTTATGTCTGCAAGTGGATATTTGGACCTCTTTGAGGGCTTCGTTGCAAACGGGGTTTCTTCCTTTCATGCTAGACTAAGAAGAGTTCTCAGGAACTTTTTTGTGTTGTGTGTATTCAACTCACAGAGTTGAACCTTGCTTTAGAGAGAGCAGATTTGAAACACTCTTGCTGTGGCATTTTCAGGTGGAGATTTCAAGCGATTTGAGGACAATTGCAGAAAAGGAAATATCTTCGTATAATAACCAGACAGAATCATTCTCAGAAAGTGCTTTGTGATGTGTGCGTTCAACTCACAGAGTTTAACCTTTCTTTTCATAGAGGAGTTTGGAAACACACTGTTTGTAAAGTCTGCAAGTGGAAATATGGACCTGTTTGAGGCCTTCGTTGGAAACGGGATTTCTTCATTGAATGCTAGACGGAAGAATTCTCAGCAAATTCTTTGTGTTGTGTGCATTCAACTCCCAGAGTGGAACGTCCATTTAGACAGAGCAGATTTGAAACACTCATTTTGCGGAATTTGCAAGTGGAGATTGCTAGCCATTTGATGCCAACAGTAGAAAGGGAAATATCTTCAAATAAAAACTAGACAGAATCATCCTCAGAAAATTCTTTGTGATGTGTGCGTTCAACTCACATAGTTTAACCTTTCTTTTCATAGAGCAGTTTGGAAACTCTCTGTTGGTAATGTGTGCATGTGGATATATGGACCGCTTTGAGGCCTTCGTTGGAAACGGGATTTCTTCATTTCATGCTAGACACAAGAATTCTCAGTAACTTCTTTGTGTTGTGTGTATTAAACTCACAAACTGGAACGTCCCTTTACACAGAGCAGATTTGAAACACTCTTTTTGTGGAATTTGCAAGTGGAGATTTCAAGCGATTTGTTGCCAACAATAGAAAAGGAAATATCTGCAAATAAAAACTAGACAGAATCATTCTCAGAAAGTGCTTTGTGATGTGTGCGTTCAACTCACAGAGTTTAACCTTTCTTTTCATAGAGGAGTTTGGAAACACACTGTTTGTAAAGTCTGCAATTGGATATATGGACCTGTTTGAGGCCTTCGTTGGAAACGGGATTTCTTCATTGAATGCTAGACGGAAGAATTCTCAGTAAATTCTTTGTGTTGTGTGCATTCAACTCACAGAGTGGAACGTCCCTTTAGACAGAGCAGATTTGAAACACTCTTTTTGCGGAATTTGCAAGTGGAGATTTCTAGCCATTTGATGCCAACAGTGGAAAGGGAAATATCTTCAAATAAAAACTAGACAGAATCATCCTCAGAAAATTCTTTGTGATGTGTGCGTTCAACTCACATAGTTTAACCTTTCTTTTTATA
图1测序结果显示候选circRNAs分子在胃癌组(Gastric cancer)和对照组(Control)血清细胞外囊泡中的表达水平。
三、qRT-PCR验证circRNAs表达
1、收集健康对照44例、胃癌患者112例,提取血清细胞外囊泡RNA。
细胞外囊泡提取步骤根据exoEasyMaxi-76064试剂盒说明书进行,血清标本为1ml。
细胞外囊泡中RNA的提取步骤根据exoRNeasy Serum/Plasma Midi-77044剂盒说明书进行。
2、设计circRNAs分子(Chr10q11、Chr1p11、Chr7q11)的特异性引物,分别如下所示:
F:5'-TCGGTTCCATTTGATGATGA-3'(SEQ ID No.4)
R:5'-CGAATGGAATGGAATGGAA-3'(SEQ ID No.5),产物大小为214bp。
F:5'-TTCAGCCGCTTTGAGGTC-3'(SEQ ID No.6)
R:5'-CCAACGAAGGCCACAAGA-3'(SEQ ID No.7),产物大小为196bp。
F:5'-TTTGAGGCCTTCGTTGGA-3'(SEQ ID No.8)
R:5'-CCCTTTCCACTGTTGGCA-3'(SEQ ID No.9),产物大小为192bp。
3、circRNAs的逆转录及PCR
circRNAs的逆转录及PCR过程分别根据试剂盒进行(QP006+QP001)。计算方法为2-ΔΔCt方法。逆转录条件为65℃10min,37℃60min,85℃5min。扩增条件为95℃10min,40个循环(95℃15s,62℃20s,72℃10s)。
4、验证结果及统计学分析:
去除表达水平较低(Ct值大于35)的circRNAs分子。
采用SPSS 25.0软件(SPSS Inc.,USA)。连续变量采用中位数(Median)和平均值±标准差
Figure BDA0002950732580000181
表示;两组比较采用t检验或Mann-Whitney U检验。通过绘制受试者工作特征(ROC)曲线和计算相应的曲线下面积(AUC)来判断诊断能力。最佳cutoff值选取为灵敏度和特异性之和最大所对应的值,结果P<0.05(双侧)为有统计学差异。
结果显示Chr10q11、Chr1p11、Chr7q1在胃癌中的表达均高于健康对照(P<0.01)(图2);且均对胃癌具有较好的诊断价值(图3),Chr10q11、Chr1p11、Chr7q11的诊断效率如下:
Chr10q11:AUC为0.726(95%CI:0.649-0.795),敏感性为76.8%(95%CI:67.9-84.2%),特异性为65.9%(95%CI:50.1-79.5%)。
Chr1p11:AUC为0.822(95%CI:0.753-0.879),敏感性为82.1%(95%CI:73.8-88.7%),特异性为77.3%(95%CI:62.2-88.5%)。
Chr7q11:AUC为0.749(95%CI:0.673-0.815),敏感性为79.5%(95%CI:70.8-86.5%),特异性为59.1%(95%CI:43.3-73.7%)。
Chr10q11+Chr1p11+Chr7q11:AUC为0.839(95%CI:0.772-0.893),敏感性为73.2%(95%CI:64.0-81.1%),特异性为84.1%(95%CI:69.9-93.3%)。
以上所述仅为本申请的优选实施例而已,并不用于限制本申请,尽管参照前述实施例对本申请进行了详细的说明,对于本领域的技术人员来说,其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换。凡在本申请的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本申请的保护范围之内。
SEQUENCE LISTING
<110> 山东大学齐鲁医院
<120> 细胞外囊泡circRNAs作为胃癌诊断标志物的应用
<130> 202120939
<160> 9
<170> PatentIn version 3.5
<210> 1
<211> 10750
<212> DNA/RNA
<213> Chr10q11
<400> 1
tccatttgat catgattcca tttgattcca ctcgatgatt ccattcgatt ccattcaatg 60
atgattccat tcgagttcat tgactattcc attccattcc attcgatgat tccatttgag 120
tccattcgat gattctattc gattgcattc gataattcca ttcgattgca tttgataatt 180
ccatttgatt ccatttgagg ataattccat ttgagtccat tcgatgattg ttccattcga 240
ttctattcgg tgattccatt cgattctatt tgataatgat tccattcgag accatgcgat 300
gattccattc aattccattc aataatgatt ccattcgagt ccattcaatg attccattca 360
agtccatttg ttgattccat ctgattccat tcaatgaatc cattcgattc cattctatga 420
tggttccatt catttctatc tgatgataat tccattcaat tccattcaat gattccattc 480
gattccattt gatgatgatt tcaatcaatt tcatttgatg attccattcg aatccatttg 540
atgatgagtc catccatttc aatttcataa ttccattcgt ttcaattcga tggtgtttcc 600
attcgattcc attcgatgtt aattccatta gtttccattg gatgatgatt ccatttgagt 660
ccattcgatc atgatcacat tggatttcat tccataattc tattctattc catttcatga 720
tgattccatc tgattccatt tgatgattcc attcgattcc attctatgat gattccattc 780
atttccatct gatgatgatt ccaattgatt catttcaatg attccattcg attccatttg 840
atgatgattg caatgaattt cattcgatga caccatttga atccattcga tgatgagtcc 900
atccatttca atttcatgat aattccattc ttttcaattc gatggtgttt ccatttgatt 960
gcattcgatg ttgattcctt tagtttccat tggatcatga ttccattcga gtccattcga 1020
tgatcatcac attggatttc attccataat tctaaccgat tccatttgat gatgattcca 1080
tctgattcca tttgatgatt ccattcgatt ccattcaatg acgattccat tcgtttccat 1140
ccaatgatga ttccattcga ttcctttcaa tgattattcc cttcgagtcc attcgatgat 1200
tccattcgat tccattcgaa gatgattgca ttcgagtcca tggattattc cattccattc 1260
cattagatga ttccattcga gtccattcga tgattatctt cgattccatt caataattca 1320
gtttgattcc gtttgatgtt gattccattt tagtccattc gatgataatt ccattcgatt 1380
ctatgcgatg attccattcc attccatttg aagatgatta aattcgagac cattcagtga 1440
ttgcattcaa ttcattcgat gacgattcca ttcaattccg ttcaaagatt ccattaggtt 1500
tcatttgatg atgattccat acgattccat tagatgatga ctcctttcat ttccactcga 1560
tgatgattcc attcgtttcc attcgacgat gattccattt gattccgttc aatgattatt 1620
ccattcgagt ccattcgatg attccattcg attctattcg atgatgattg cattcgggtc 1680
catggattat tccattccat tccattagat gattccattc gtggccattt gatgattctc 1740
ttcgattcca ttcgataatt ccgtttgact ccgtttgatg ttgattccat tcgagtccat 1800
tcaatgataa ttccattcga ttctatgcga tgatttcatt cctttccatt tgatgatgat 1860
tccattcgag accattcgat gattgcattc aattcattcg atgacgattc cattcaattc 1920
cattcaatga ttccattaga ttccatttga tgatgattcc attcgattcc attcaatgat 1980
gattccattc gagttcattg actattccat tccattccat tctatgattc cattcgagtc 2040
cattagatga ttctattcga ttgcatttga taattccatt cgattgcatt cgatatttcc 2100
attcgattcc atttgaggat aattccattt gagtccattc aatgattctt ccattcgatt 2160
ctattcggtg attccattcg attccatttg atgatgattc cattagagac cattccatga 2220
ttccattcaa ttccattcaa taaagattgc attcgagtcc attcaatgtt tccattcaag 2280
tccattcaat gattccatct gattccattc aatgaatcca ttcgattcca ttctatgatg 2340
attccattca tttccatctg atgatgattc cattcgattc cattcaatga ttccattcga 2400
ttccatttga tgatgatttc aatcaatttc attcgatgat tccattcgaa tcctttcgat 2460
gatgagtcca tccatttcaa attcatgata attccattcc tttcaattcg atggtgtttc 2520
cattcgattc cattcgatgt tgattccatt agtttccatt ggatgatgat tccgttcgag 2580
tccattcgat gatgatgaca ttggatttca ttccataatt ctactcgatt ccatttgatg 2640
atgattccgt ctgcttccat ttgatgattc cattcgatgc cattcgatga tgattccatt 2700
cgattccgtt caatgattat tccactcgtg tccattcgat gattccattc gattccattc 2760
gatgatgatt gcattcgagt ccatggaata ctccattcca ttccattaga tgattccatt 2820
cgagtccatt cgatgatgct cttcgattcc attcgataat tccgtttgat tccgtttgat 2880
gttgattcaa ttccagtcca ttcgatgata attccattcg attctatgcg atgattccat 2940
tctaatccat ttgaagatga ttccattcga gaccattcga tgattgcatt caatacattc 3000
tatgacgatt ccattcaatt ccgttcaatg attccattcg attccatttg atgatgattc 3060
cattcgattc catttgatga agataccatg cgattccatt agatgatgac tcctttcatt 3120
tccattcaat gaggattcca ttcggttcca tttgatgatg attcctttga attccattgg 3180
atgacaattc cattcaatac caattgatta tggttatttt tgattccgtt tgatgatgat 3240
tatattcgat tccatttgat catggttcca ttcgattcca ctcaatgatt ccattcgatt 3300
ccattcaatg attattccat tcgagttcat tgactattcc attccattcc attcgacgat 3360
tccaatcgag tcctttcgat gattctattt gattgcattc gataattcca ttcgattgca 3420
ttcgataatt ccattcgatt ccatttgagg ataattccat ttgagtccat tcgatgattg 3480
ttccattcga ttctattcgg tgattccatt cgattccatt tgataaggat tcctttcgag 3540
accattcgat gattccattc aattccattc aataatgatt tcattcgagt ccattcagtg 3600
attgcattca agtcctcttg atgattccat ctgattccat tcaatgaatc cattcgattc 3660
cattctatga tgattccatt cgtttccatc tgatgatgat tccattcgat tccattcaat 3720
gattccattc gattcaattt gatgatgatt tcaatcaatt tcattcgatg attacatttc 3780
gaatccattc gatgatgagt ccatccattt caatttcatg ataattccat tcgtttcaat 3840
tcgatggtgt ttccattcga ttccattcga tgttgattcc attagtttcc attggatgat 3900
gattccattc gagtccattc gatgatgatc acattggatt tcattccata attctactca 3960
attccatttg atgatgattc catctgattc catttgatga ttccattcaa ttccattcga 4020
tgatgattgc attcgtttcc atccaatgat gattccattc gattccgttg aatgattgtt 4080
ccattcgagt ccattcgatg attccattcg attccattcg atgatgagag cattcgagtc 4140
catggattat tccattccat cccattagat tatttcattc gagtccattc gatgattctc 4200
ttcgattgca tttgataatc ccgtttgatt ccgtttgatg ttgattccat ttgagtccat 4260
ttgatgataa ttccattcga ttctatgcga tgattccatt ccattccatt tgaagatgat 4320
tccattcgag accattcaat gattgcatta aattcattcg atgacgattc cattcaattc 4380
cgttcaatga ttccattaga atccattcga tgatgattcc attcgattcc atttcatgat 4440
gattccatgc gattccatta gatgatgact cctttcactt ccattcgatg atgattccat 4500
tcgtttccat tcgacgatga ttccatttga ttccgttcaa tgattattcc attcgagtcc 4560
attcgatgat tccattcgat tctattcgat gatgattgca ttcgggacca tggattattc 4620
cattccattc cattagatga ttccattcgt ggccattcga tgattctctt cgattccatt 4680
cgataattcc gtttgattcc gtttgatgtt gattccattc gactccattc aatgataatt 4740
ccattcgatt ctttgcgatg attccattcc tttccatttg atgatgattc cattcgagac 4800
caatcgatga ttacattcaa ttcattcgat gacgattcca ttcaattcct ttcaatgatt 4860
ccattagatt ccatttgatg atgattccat tcaaatccat ttgatgatga ttccatgcga 4920
ttccattatt tgatgactcc tttcatttcc attcaatgag gtttccattc ggttccattt 4980
gatgatgatt cctttgaatt ccatttgatg acaattccat tcaataccaa ttgatgattg 5040
ttatttttga ttccatttga tgattacatt cgattccatt taatcgtgat tccattcgat 5100
tccactcgat gattccattc gattccattc aatgatgatt ccattcgagt tcattgacta 5160
ttccattccg ttccattcga tgataccatt cgagtccatt cgatgattct actcgattgc 5220
attcgataat tccattcgat tgcatttgat aattccattt gattccagtt gaggataatt 5280
ccttttgagt ccattcgatg attgttccat tcgattctat tcggtgattc cattcgattc 5340
cattggataa tgattccatt caataccatt cgatgattcc attctattcc attcaataat 5400
gattccattc gagtccattc aatgattcca ttcaagtcca ttcgatgatt ccatctgatt 5460
ccattcaatg aatccattcg attccattat atgatgattc cattcatttc catctgatga 5520
ggattccttt cgattccatt caatgattcc attcgattca atttgatgat gatttcaatc 5580
aatttcattc gatgattcca ttcgaatcca ttcggtgatg aatccatcca tttcaatttc 5640
atgataattc cattcatttc aattcgatgg tgtttccatt cgattccatt cgatgttgat 5700
tccattagtt tccattggat gatggttcca ttcgagtcca ttcaatgatg atcacattgg 5760
atttcattcc ataattctat tcgattccat ttgatgatga ttccatctga ttccatttga 5820
tgattccatt cgattccatt cgatgatgat tccattcgtt tccatctgat gatgattcca 5880
ttcgattccg ttcaatattt attccattcg agtccatttg acgattccat ttaattccat 5940
ttgatgatga ttgcatacga gtccatcaat tattccattc tatttcatta gatgattcca 6000
ttcgagtcca ttcgatgatt ctcttcgatt ccattcgata actccgtttg attccgtttg 6060
atgttgattc catctgagtc ctttcgatga taattccatt cgaatctata cgatgattcc 6120
tttccattcc atttggagat tattccattc gagaccattc gatgattgca ttcaatccat 6180
tcgatgacga ttcctttcaa ttcccttcaa tgattccatt agattccatt cgatgatgat 6240
tccattcgat tccatttgat gatgattcca tgcgattcca atagatgatg actcctttca 6300
tttccattcg atgatgtttc cattcgtttc cgttcggcga tgattccatt cgatcccgtt 6360
caatgattat tccattcgag ttcatttgat gattccattg ggttctattc gatgatgatt 6420
gcattcgtgt ccatggataa ttccattcca ttccattaga tgattccatt cgtggccatt 6480
cgatgatgct cttcgattcc attcgataat tccgtttgat tccgtttgat gtttattcga 6540
tttgaatcca ttcaatgata attccattcg attctatgcg atgattccat tcctttccat 6600
ttgaagatga ttccattcca gaccattcga tgattgcatt caattcattc gatgacgatt 6660
ccattcaatt ccgttcaatg attccattcg attccatttg atgatgattc catgcgattc 6720
cattagatga tgactccttt catttccatt caatgaggat tccattcggt tccatttgat 6780
gatgattcct ttgaattcca tttgatgaca attccattca ataccaattg acgatgttta 6840
tttttgattc catttgatga tgattacatt cgattccatt tgatgatgat tccatttgat 6900
tccactcgat gattccattc tattccattc aatgatgatt ccattcgagt tcattgacta 6960
ttccattcca ttccattcga tgattccatt cgagtccatt cgatgattct atttgattgc 7020
attcgataat tccattcggt ccattcgata attccatttg attccatttg agaataattc 7080
catttgagtc catttgatga ttgttccatt cgattctatt cggtgattcc attcgattcc 7140
aattgataat gattccattc gagaccattc gatgattact ttctattcca ttcaataatg 7200
attccattcg agtccattca atgattccat tcaagtccat tcgatgattc cttctgattc 7260
cattcaatga atccattcga atccattgtt tgatgattcc attcatttcc atctgaagat 7320
gattccattc gattccattc aatgattcca ttcgattcca ttcgatgatg attccattcg 7380
tttccatctg atgaagattc cattcgattc cgttcaatgt ttactccatt tgattccatt 7440
cgctgattcc attcgattcc atttgatgat gattgcattc gagtccatgg attattccat 7500
tctattttat tagatgattc cattcgtggc catttgatga ttctcttcga ttccattcga 7560
taattccgtt tgattccgtt tgatgttcat tccattcgtt tcctttcaat gattccattc 7620
aagtccattc gatgattcca tctgattcca ttcaatgaat ccattcgatt ccattctatg 7680
atgattccat tcttttccat ctgatgatga ttccattcga ttccattcaa tgattccatt 7740
cgattccatt tgatgatgat ttcaatcaat ttcattcgat gattccattc gaatccattc 7800
gatgatgagt ccatccattt caatttcatg ataattccat tcgtttcaat tcgatggtgt 7860
ttccattcga ttccattcga tgttgattcc attagtttcc agtggatgat gattccgttc 7920
gattccattt gatgatgatc acattggatt tcattccata attgtatttg attccatttg 7980
atgatgattc catctgattc catttcatga ttccattcga ttccattcga taatgattcc 8040
attcgtttcc atccgatgat gattccattc gattccgttc aatatttatt ccattcgagt 8100
ccattcgacg attccattcg attccatttg aggatgattg cattctagtc catggattat 8160
tccattctat ttcattagat gattccattc gagtccattc gatgattctc ttcgattcca 8220
ttcgataatt ccgtttgatt ccgtttgatg ttgattccat ttgagtccat tcgatgttaa 8280
ttccattcga ttctatgcga tgattccatt ccattcattt tgaagatgat tccattcgag 8340
accattcgat gattgcattc aattcattcg atgatgattc cattcaattc cgttcaatga 8400
ttccattaga ttccattcga tgatgattcc attcgattcc atttgatgat gattccatgc 8460
gattccattg gatgatgacc cctttcattt ccattctatg atgattccat ttgtttcctc 8520
cattcgacga tgattccatt cgattccgtt caatgattat tccattcgag tccatacgat 8580
gattccattc gattctattc gatgatgatt acattcgtgt ccatggatta tttcattcca 8640
ttccattaga ggattccatt cgaggccatt cgatgattct cttcgattcc attcgataat 8700
tccgtttgat tccgtttgat gttgattcca ttcgagtcca ttcaatgaca attccattcg 8760
attctatgcg atgattccat tcctttccat ttgaagatga tgccattcga gaccattcga 8820
tgattgcatt caattcattc gatgacgatt ccattcaatt ctgttcaatg attccattag 8880
attccattcg atgattattc cattcgattc catttgatga tgattccatg cgattccatt 8940
agatgatgat tcctttcatt tccattcaat gaggattcca ttcggttcca tttgatgatg 9000
attcctttga attccatttg atgacaattc cattcaatac caactgatga tggttatttt 9060
tgattccatt tgatgatgat tacacttgat tccatttgat catgattcta ttcgattcca 9120
ctcgatgatt ccattcgatt ccattcaatg atgattccat tcgagttcat tgactattcc 9180
attccattcc attcgatgat tccattcgag tccattcgat gattctattt gatggcattc 9240
tataattcca ttcgattgca tttgataaat ccattcaatt ccatttgagg ataatgccat 9300
ttgagtccat tccatgattg ttccattcga ttccattcga taattattcc attcgattcc 9360
atttgataat gattctattc gagaccattc gatgattcca ttgaattcca ttcaataatg 9420
attccattcg agtccattca atgtttccat tcaagtccat tcgatgattc tatgtgattc 9480
cattcaatga atccattcga ttccattcaa tgatgattgc attcatttcc atatgatgat 9540
gattccattc gattccattc aatgattcca ttcgattcca ttagatgatg atttcaatca 9600
atttcattcg atgattccat tcgaatccat tcgatgatga gtccttcctt ttcaatttca 9660
tgataattcc attcgtttca attcgatggt gtttccattc gattccattc gatgttgatt 9720
ccattagttt ccattggatg atgattccat tcaagtccgt tcgatgatga tcacattggg 9780
tttcattcca taattctatt cgattccatt tgatgatgat tccatctgat tccatttgat 9840
gattccattc cattcaattc gatgatgatt ccattcgttt ccatccggtg aagactgcat 9900
tggattccgt tcaatgttta ttcctttcga gtccattcga cgattccatt cgattccatt 9960
cgatgatgat tccatgcgat tccatttgat gatgattcca tgcgattcca ttagatgatg 10020
actcctttca tttgcattcg atgatgattc catttgtttc cgttcgacga tgattccatt 10080
cgattccgtt caatgattat tccattcgag tccattcgat gattccattc gattctattc 10140
gatgatgatt gcattcgagt ccatggatta ttccattcca ttccattaga tgattccatt 10200
cgtggccatt cgatgattct ttccgattcc attcgataat tccgtttgat taagtttgat 10260
gttgattcca ttcggtccat tcaatcataa ttccattcga ttctatgcga tgattccatt 10320
cctttccatt tgtagatgat tccattcggg accattcgat gattgcattc aattcattag 10380
atgacggttc cattcaattc cgttcaatga taccattaga tttgatttga tgatgattcc 10440
atttaatgat gattccattc gattccattt gatgatgatt ccatgcgatt ccattagatg 10500
atgactcctt tcatttccat tcaatgagga ttccattcgg ttccatttga tgatgattcc 10560
tttgaattcc atttgatgac aattccattc aataccaatt gatgatggtt atttttgatt 10620
ccatttgatg atgattacat tcgattccat ttgatcatga ttccatttga ttccactcga 10680
tgattccatt cgattccatt caatgatgat tccattcgag ttcattgact attccattcc 10740
attccattcg 10750
<210> 2
<211> 408
<212> DNA/RNA
<213> Chr1p11
<400> 2
ctctgtttgt aaagtctgta agtggatatt ctgacatctt gtggccttcg ttggaaacgg 60
gatttcttcc tattctgcta gacagatgaa ttctcagtaa cttccttgtg ttgtgtgtat 120
tcaactcaca gagttgaacg atcctttaca cagagcagac ttgaaacact ctttttgtgg 180
aatttgcaag tggagatttc agccgctttg aggtcaatgg tagaaaagga aatatcttcg 240
tatagaaaca agacagaatg attctcagaa actcctttgt gatgtgtgcg ttcaactcac 300
agagtttaac ctttcttttc atagagcagt taggaaacac tctgtttgta aagtctgtaa 360
gtggatattc tgacatcttg tggccttcgt tggaaacggg atttcttc 408
<210> 3
<211> 3029
<212> DNA/RNA
<213> Chr7q11
<400> 3
gcaagtggag atttctagcc atttgatgcc aacagtggaa agggaaatat cttcaaataa 60
aaactagaca gaatcatcct cagaaaattc tttgtgatgt gtgcgttcaa ctcacatagt 120
ttaacctttc tttttataga gcagtttgga aacactttgt tggtaacgtc tgcaagtgga 180
tatatggaac gctttgaggc tttcgttgga aacgggattt cttcatttca tgctagacag 240
aagaattctc agtaacttct ttgtgttgtg tgtattcaac tcacagactg gaacgtcgct 300
ttacacagag cagatttgaa acactctttt tgtggaattt gcaagtggag atttcaagcg 360
atttgatgcc aacagtagaa aaggaaatat ctgcaaataa aaacaagaca gaatcattct 420
cagaaagtgc tttgtgatgt gtgcgttcaa ctcacagagt ttaacctttc ttttcataga 480
ggagtttgga aacacactgt ttgtaaagtc tgcaagtgga tatatggacc tgtttgagac 540
cttcggtgga aacgggattt taacatataa tgctagacgg aagaattctc agtaaattct 600
atgtgttgtg tgctttcaac tcacatagtt taacctttct tttcatagag cagtttggaa 660
acactctgtt ggtaatgtct gcaagtggat atatggaccg cttggaggct ttcgttggaa 720
acgggatttc ttcatttcat gctagacaga agaattctca gtaacttctt tgtgttgtgt 780
gtattcaact cacagactgg aacgtccctt tacacagagc agatttgaaa cactcttttt 840
gtggaacttg caagtggaga tttcaagcga tttgatgcca acagtagaaa aggaaatatc 900
tgtaaataaa aacaagacag aatcattctc agaaagtgct ttgtgatgtg tgcgttcaac 960
tcacagagtt tatcctttct tttcatagag gagtttggaa acacactgtt tgtaaagtct 1020
gcaattggat atatggacct gtttgaggcc ttcgttggaa acgggatttt atcatataat 1080
gctagacgga agaattctca gtaaattctt tgtgttgtgt gcattcaact cacagagtgg 1140
aacgtccctt tagacagagc agatttgaaa cactgttttt gcggaatttg caagtggaga 1200
tttctagcca tttgatgcca acagtagaaa gggaaatatc ttcaaataaa aaccagacag 1260
aatcattctc agaaaattct ttgtgatgtg tgcgttcaac tcacatagtt taacctttct 1320
tttcatagag cagtttggaa acactctgtt tgtaaagtct gcaagtggat atatggaccg 1380
cattgaggcc ttcgttggaa acgggatttc ttcatttcat gctagacaga agaattctca 1440
gtaacttctt tgtgctgtgt gtattcaact cacagagtgg aacgtccctt tacacagagc 1500
agatttgaaa cactcttttt gtggaatttg caagtggaga tttcaagcga tttgatgcca 1560
acagtagaaa aggaaatatc ttcaaataaa aactagacag aatcattctc agaaactact 1620
ttgtgatgtg tgccttcaac tcacagagtt taacctttct tttcttagag cagtttagaa 1680
acactctgct tgttatgtct gcaagtggat atttggacct ctttgagggc ttcgttgcaa 1740
acggggtttc ttcctttcat gctagactaa gaagagttct caggaacttt tttgtgttgt 1800
gtgtattcaa ctcacagagt tgaaccttgc tttagagaga gcagatttga aacactcttg 1860
ctgtggcatt ttcaggtgga gatttcaagc gatttgagga caattgcaga aaaggaaata 1920
tcttcgtata ataaccagac agaatcattc tcagaaagtg ctttgtgatg tgtgcgttca 1980
actcacagag tttaaccttt cttttcatag aggagtttgg aaacacactg tttgtaaagt 2040
ctgcaagtgg aaatatggac ctgtttgagg ccttcgttgg aaacgggatt tcttcattga 2100
atgctagacg gaagaattct cagcaaattc tttgtgttgt gtgcattcaa ctcccagagt 2160
ggaacgtcca tttagacaga gcagatttga aacactcatt ttgcggaatt tgcaagtgga 2220
gattgctagc catttgatgc caacagtaga aagggaaata tcttcaaata aaaactagac 2280
agaatcatcc tcagaaaatt ctttgtgatg tgtgcgttca actcacatag tttaaccttt 2340
cttttcatag agcagtttgg aaactctctg ttggtaatgt gtgcatgtgg atatatggac 2400
cgctttgagg ccttcgttgg aaacgggatt tcttcatttc atgctagaca caagaattct 2460
cagtaacttc tttgtgttgt gtgtattaaa ctcacaaact ggaacgtccc tttacacaga 2520
gcagatttga aacactcttt ttgtggaatt tgcaagtgga gatttcaagc gatttgttgc 2580
caacaataga aaaggaaata tctgcaaata aaaactagac agaatcattc tcagaaagtg 2640
ctttgtgatg tgtgcgttca actcacagag tttaaccttt cttttcatag aggagtttgg 2700
aaacacactg tttgtaaagt ctgcaattgg atatatggac ctgtttgagg ccttcgttgg 2760
aaacgggatt tcttcattga atgctagacg gaagaattct cagtaaattc tttgtgttgt 2820
gtgcattcaa ctcacagagt ggaacgtccc tttagacaga gcagatttga aacactcttt 2880
ttgcggaatt tgcaagtgga gatttctagc catttgatgc caacagtgga aagggaaata 2940
tcttcaaata aaaactagac agaatcatcc tcagaaaatt ctttgtgatg tgtgcgttca 3000
actcacatag tttaaccttt ctttttata 3029
<210> 4
<211> 20
<212> DNA
<213> 人工序列
<400> 4
tcggttccat ttgatgatga 20
<210> 5
<211> 19
<212> DNA
<213> 人工序列
<400> 5
cgaatggaat ggaatggaa 19
<210> 6
<211> 18
<212> DNA
<213> 人工序列
<400> 6
ttcagccgct ttgaggtc 18
<210> 7
<211> 18
<212> DNA
<213> 人工序列
<400> 7
ccaacgaagg ccacaaga 18
<210> 8
<211> 18
<212> DNA
<213> 人工序列
<400> 8
tttgaggcct tcgttgga 18
<210> 9
<211> 18
<212> DNA
<213> 人工序列
<400> 9
ccctttccac tgttggca 18

Claims (10)

1.一种胃癌诊断标志物,其特征在于,为细胞外囊泡circRNA Chr10q11、Chr1p11、Chr7q11中的一种或多种的组合。
2.细胞外囊泡circRNA Chr10q11、Chr1p11、Chr7q11中的一种或多种的组合在作为胃癌诊断标志物方面的应用。
3.根据权利要求2所述的应用,其特征在于,所述应用为:检测样本中细胞外囊泡circRNA Chr10q11、Chr1p11、Chr7q11中的一种或多种的表达。
4.根据权利要求3所述的应用,其特征在于,所述样本包括血液、病理组织和排泄物;优选为血液。
5.根据权利要求3所述的应用,其特征在于,所述检测方法选自PCR方法、免疫印迹方法、酶联免疫吸附方法和基因工程方法。
6.提取或检测细胞外囊泡circRNA Chr10q11、Chr1p11、Chr7q11中的一种或多种的试剂或试剂盒在制备胃癌诊断产品中的应用。
7.根据权利要求6所述的应用,其特征在于,所述胃癌诊断产品包括试剂盒、药品和诊断器械。
8.细胞外囊泡circRNA Chr10q11、Chr1p11、Chr7q11中的一种或多种的组合作为靶点在制备治疗胃癌的药物中的应用;
优选地,所述药物抑制细胞外囊泡circRNA Chr10q11、Chr1p11、Chr7q11中的一种或多种的表达。
9.一种胃癌诊断试剂盒,其包括细胞外囊泡circRNA Chr10q11、Chr1p11、Chr7q11中的一种或多种的检测相关试剂;
优选地,所述试剂盒还包括用于配制反转录反应体系的试剂和/或用于配制qPCR反应体系的试剂。
10.根据权利要求9所述的试剂盒,其特征在于,所述试剂盒检测样本细胞外囊泡circRNA Chr10q11、Chr1p11、Chr7q11中的一种或者多种的表达。
CN202110206105.2A 2021-02-24 2021-02-24 细胞外囊泡circRNAs作为胃癌诊断标志物的应用 Active CN112921090B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110206105.2A CN112921090B (zh) 2021-02-24 2021-02-24 细胞外囊泡circRNAs作为胃癌诊断标志物的应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110206105.2A CN112921090B (zh) 2021-02-24 2021-02-24 细胞外囊泡circRNAs作为胃癌诊断标志物的应用

Publications (2)

Publication Number Publication Date
CN112921090A true CN112921090A (zh) 2021-06-08
CN112921090B CN112921090B (zh) 2022-05-03

Family

ID=76171586

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110206105.2A Active CN112921090B (zh) 2021-02-24 2021-02-24 细胞外囊泡circRNAs作为胃癌诊断标志物的应用

Country Status (1)

Country Link
CN (1) CN112921090B (zh)

Also Published As

Publication number Publication date
CN112921090B (zh) 2022-05-03

Similar Documents

Publication Publication Date Title
US20220186320A1 (en) MicroRNA Marker Combination for Diagnosing Gastric Cancer and Diagnostic Kit
CN111172287B (zh) 外泌体lncRNA RN7SL5P作为内参基因在胃癌lncRNA检测中的应用
CN113604572B (zh) 用于肺癌诊断的试剂盒、装置及方法
CN112921090B (zh) 细胞外囊泡circRNAs作为胃癌诊断标志物的应用
CN110257514A (zh) 一种新的食管癌血液miRNA标志物及其应用
CN111455057B (zh) 用于肺癌诊断的试剂盒、装置及方法
CN108517361B (zh) Zfpm2-as1在制备胰腺相关疾病诊断试剂盒中的应用
CN114672560A (zh) 通过外泌体miRNA标志物鉴定结直肠癌状态的检测试剂盒和方法
CN117051103A (zh) 用于诊断结直肠癌的血浆外泌体环状rna生物标志物及其应用
CN114752676A (zh) 检测hsa_circ_0099132的试剂在制备人结直肠癌辅助诊断试剂盒中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant